Dopamine agonists cost effective for cotherapy of Parkinson's disease?

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.332, 2001-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Are Dopamine Receptor Agonists Neuroprotective in Parkinson's Disease?

By Le W-D. Jankovic J.

Drugs & Aging, Vol. 18, Iss. 6, 2001-06 ,pp. : 389-396

Adis International

Access to resources Recommend Favorite

Dopamine D Receptor Agonists: The Way Forward for the Treatment of Parkinson's Disease?

By Vermeulen R.J. Drukarch B. Wolters E.C. Stoof J.C.

CNS Drugs, Vol. 11, Iss. 2, 1999-02 ,pp. : 83-91

Adis International

Access to resources Recommend Favorite

Is NADH Effective in the Treatment of Parkinson's Disease?

By Swerdlow R.H.

Drugs & Aging, Vol. 13, Iss. 4, 1998-10 ,pp. : 263-268

Adis International

Access to resources Recommend Favorite

Dopamine Agonists in Parkinsons Disease: What is Their Role in Early Treatment?

By Stocchi F.

CNS Drugs, Vol. 10, Iss. 3, 1998-09 ,pp. : 159-170

Adis International

Access to resources Recommend Favorite

Sleep Attacks and Dopamine Agonists for Parkinsons Disease: What is Currently Known?

By Zesiewicz T.A. Hauser R.A.

CNS Drugs, Vol. 17, Iss. 8, 2003-01 ,pp. : 593-600

Adis International

Access to resources Recommend Favorite